Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -106.78% is 298% below its 3-year average of -26.82%, around the middle of its 3-year range (-164.16%–3.26%).
99.09% below its 12-month average of -53.63%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2025 (2025-12-31): 3.26%.
NET PROFIT MARGIN
-106.78%
NET PROFIT MARGIN AVG TTM
-53.63%
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-99.09%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 567 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Basel Medical Group Ltd Ordinary Shares
Market Cap
$5.40M
Net Profit Margin
-106.78%
TTM Avg
-53.63%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.36M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.35M
Net Profit Margin
-612568.11%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.33M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.57M
Net Profit Margin
-294.91%
TTM Avg
-320.57%
3Y Avg
-453.36%
5Y Avg
-361.46%
Market Cap
$5.21M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1794.91%
5Y Avg
-2605.04%
Market Cap
$5.63M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$4.99M
Net Profit Margin
-4011.86%
TTM Avg
-2005.93%
3Y Avg
-2671.67%
5Y Avg
-1781.12%
Market Cap
$5.82M
Net Profit Margin
-9366.75%
TTM Avg
-6298.14%
3Y Avg
-3910.26%
5Y Avg
-3305.87%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Basel Medical Group Ltd Ordinary Shares (BMGL) | $5.40M | -106.78% | -53.63% | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.36M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.35M | -612568.11% | 0.00% | 0.00% | 0.00% |
| Alzamend Neuro Inc (ALZN)vs › | $5.33M | 0.00% | 0.00% | 0.00% | 0.00% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.57M | -294.91% | -320.57% | -453.36% | -361.46% |
| Imunon, Inc. (IMNN)vs › | $5.21M | 0.00% | 0.00% | -1794.91% | -2605.04% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | -4011.86% | -2005.93% | -2671.67% | -1781.12% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.82M | -9366.75% | -6298.14% | -3910.26% | -3305.87% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.96M | -118.27% | -13237.88% | -7961.50% | -5307.67% |
Operating Margin
-19.3%
Net Profit Margin
-106.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 3.26% |
| 2025-06-30 | -164.16% |
| 2024-12-31 | 0.00% |
| 2024-06-30 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-06-30 | 0.00% |